- Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
- Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
- Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
- Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
- Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
- Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
- Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
More ▼
Key statistics
On Wednesday, Disc Medicine Inc (IRON:NMQ) closed at 28.53, 11.45% above the 52 week low of 25.60 set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.79 |
---|---|
High | 29.71 |
Low | 27.79 |
Bid | 27.33 |
Offer | 29.71 |
Previous close | 27.84 |
Average volume | 406.06k |
---|---|
Shares outstanding | 24.68m |
Free float | 20.11m |
P/E (TTM) | -- |
Market cap | 687.12m USD |
EPS (TTM) | -3.49 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼